Comparison of Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis after “Allogeneic Stem Cell Transplantation from 9/10 HLA Matched Unrelated Donor’’ with Standard Graft Versus Host Disease Prophylaxis after “10/10 HLA Matched Relative Donor’’ Tr
-
Murat Yıldırım
,
Selim Sayın
,
Melda Cömert
,
Esra Şafak, Yılmaz
,
Ferit Avcu
,
Ali Uğur Ural
,
Meltem Aylı
Abstract
Background: Graft Versus Host Disease (GvHD), which can be observed at a rate of 30-80% after allogeneic stem cell transplantation (ASCT) is an important complication that adversely affects the survival and quality of the life of patients. Posttransplant cyclophosphamide (PTCy) effectively prevents GvHD after HLA-haploidentical ASCT. In our study, the use of PTCy in 1-antigen HLA-mismatched unrelated donor (9/10MMUD) ASCT was compared with standard GvHD prophylaxis in HLA-identical related donor (MRD) ASCT.
Materials and Methods: We conducted a retrospective study of the comparison of 42 patients with 9/10 MMUD ASCT receiving PTCy+Methotrexate (MTX)+Calcineurin Inhibitor (CNI) and 37 patients with HLA-identical MRD who received MTX+CNI in 3 bone marrow transplantation centers.
Results: Cumulative incidences of grade I-II (64.6% vs 45.4%, p=0.187) or grade III to IV acute GvHD (35.4% vs54.6%, p=0.187) and chronic GvHD (11.9% vs 29.7%, p=0.096) were similar in the PTCy group and control group. No statistically significant differences were observed between PTCy and the control group in overall survival rate (52.4% vs 62.2%, p=0.381), progression-free survival (1483.97 vs 1200.70 days, p=0.502), relapsed-related mortality rate (21.4% vs 16.2%, p=0.556) and treatment-related mortality rate (16.7% vs 21.6%, p=0.575).
Conclusion: With the addition of PTCy to standard GvHD prophylaxis in 9/10MMUD ASCT, the risk of GvHD due to incompatibility and unrelated transplantation is eliminated, and transplantation success is achieved with MRD ASCT. PTCy-based prophylaxis is an effective and safe strategy to prevent GvHD in 9/10 MMUD ASCT without increasing the risk of relapse and treatment-related mortality.
1. Baldemoro H, Passweg J. 30 Years EBMT Activity Survey and 2019 Annual Report. Bone Marrow Transplantation 2021; e-pub ahead of print Jan 2021(33);
2. Bashey ZA, Zhang X, Brown S, Jackson K, Morris LE, Holland HK et al. Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older. Bone Marrow Transplant. 2018; 53(6): 756-763.
3. Barkhordar M, Kasaeian A, Tavakoli S, Vaezi M, Foumani HK, Bahri T et al. Selection of Suitable Alternative Donor in the Absence of Matched Sibling Donor: A Retrospective Single-Center Study to Compare between Haploidentical, 10/10 and 9/10 Unrelated Donor Transplantation. Int J Hematol Oncol Stem Cell Res. 2021; 15(1): 51-60.
4. Greco R, Lorentino F, Albanese S, Lupo Stanghellini MT, Giglio F, Piemontese S et al. Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. Transplant Cell Ther. 2021; 27(9): 776.e1-776.e13.
5. Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR et al. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biol Blood Marrow Transplant. 2019; 25(1): 73-85.
6. Aversa F, Pierini A, Ruggeri L, Martelli MF, Velardi A. The Evolution of T Cell Depleted Haploidentical Transplantation. Front Immunol. 2019; 10: 2769.
7. de Witte M, Daenen LGM, van der Wagen L, van Rhenen A, Raymakers R, Westinga K et al. Allogeneic Stem Cell Transplantation Platforms With Ex Vivo and In Vivo Immune Manipulations: Count and Adjust. Hemasphere. 2021; 5(6): e580. doi:10.1097/HS9.0000000000000580.
8. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008; 14(6): 641-650.
9. Kanakry CG, Ganguly S, Zahurak M, Bolaños-Meade J, Thoburn C, Perkins B et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013; 5(211): 211ra157.
10. Williams L, Cirrone F, Cole K, Abdul-Hay M, Luznik L, Al-Homsi AS. Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation. Front Immunol. 2020: 11: 636.
11. Ruggeri A, Labopin M, Bacigalupo A, Afanasyev B, Cornelissen JJ, Elmaagacli A et al. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. J Hematol Oncol. 2018; 11(1): 40.
12. Carnevale-Schianca F, Caravelli D, Gallo S, Becco P, Paruzzo L, Poletto S et al. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GvHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. J Clin Med. 2021; 10(6): 1173.
13. Bradstock KF, Bilmon I, Kwan J, Micklethwaite K, Blyth E, Deren S et al. Single-Agent High-Dose Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Human Leukocyte Antigen-Matched Reduced-Intensity Peripheral Blood Stem Cell Transplantation Results in an Unacceptably High Rate of Severe Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2015; 21(5): 941-944.
14. Moiseev IS, Pirogova OV, Alyanski AL, Babenko EV, Gindina TL, Darskaya EI et al. Risk-adapted GVHD prophylaxis with post-transplantation cyclophosphamide in adults after related, unrelated, and haploidentical transplantations. Eur J Haematol. 2018; 100(5): 395-402.
15. Moiseev IS, Pirogova OV, Alyanski AL, Babenko EV, Gindina TL, Darskaya EI et al. Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil. Biol Blood Marrow Transplant. 2016; 22(6): 1037-1042.
16. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015; 21(3): 389-401.
17. Lee SJ. Classification systems for chronic graft-versus-host disease. Blood. 2017; 129(1): 30-37.
18. Boyiadzis M, Arora M, Klein JP, Hassebroek A, Hemmer M, Urbano-Ispizua A et al. Impact of chronic graftversus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia. Clin Cancer Res. 2015; 21(9): 2020–2028.
19. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010; 363(22): 2091–2101.
20. Ostronoff F, Ostronoff M, Souto-Maior AP, Domingues M, Sucupira A, Manso DA et al. Prospective trial of mycophenolate mofetilcyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies. Clin Transplant. 2009; 23(1): 33–38.
21. Ruutu T, van Biezen A, Hertenstein B, Henseler A, Garderet L, Passweg J et al. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2012; 47(11): 1459–1464.
22. Luznik L, Bolanos-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010; 115(16): 3224–3230.
23. Kanakry CG, O'Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M et al. Multi-institutional study of posttransplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014; 32(31): 3497–3505.
24. Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C et al. Phase II trial of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide after reduced-intensity busulfan/fludarabine conditioning for hematological malignancies. Biol Blood Marrow Transplant. 2015; 21(5): 906–912.
25. McCurdy SR, Kasamon YL, Kanakry CG, Bolaños -Meade J, Tsai HL, Showel MM et al. Comparable composite endpoints after HLA -matched and HLA -haploidentical transplantation with post -transplantation cyclophosphamide. Haematologica. 2017; 102(2): 391-400.
26. Kanakry CG, Tsai HL, Bolaños-Meade J, Smith BD, Gojo I, Kanakry JA et al. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014; 124(25): 3817–3827.
27. Jacoby E, Chen A, Loeb DM, Gamper CJ, Zambidis E, Llosa NJ et al. Single-agent post-transplantation cyclophosphamide as graftversus-host disease prophylaxis after human leukocyte antigen-matched related bone marrow transplantation for pediatric and young adult patients with hematologic malignancies. Biol Blood Marrow Transplant. 2016; 22(1): 112–118.
28. Holtick U, Chemnitz JM, Shimabukuro-Vornhagen A, Theurich S, Chakupurakal G, Krause A et al. OCTET - CY: a phase II study to investigate the efficacy of post -transplant cyclophosphamide as sole graft -versus -host prophylaxis after allogeneic peripheral blood stem cell transplantation. Eur J Haematol. 2016; 96(1): 27-35.
29. Mehta RS, Saliba RM, Chen J, Rondon G, Hammerstrom AE, Alousi A et al. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol. 2016; 173(3): 444-455.
30. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007; 110(13): 4576-4583.
31. Petersdorf EW, Anasetti C, Martin PJ, Gooley T, Radich J, Malkki M et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood. 2004; 104(9): 2976-2980.
32. Woolfrey A, Klein JP, Haagenson M, Spellman S, Petersdorf E, Oudshoorn M et al. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2011; 17(6): 885-892.
33. Crocchiolo R, Ciceri F, Fleischhauer K, Oneto R, Bruno B, Pollichieni S et al. HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry. Bone Marrow Transplant. 2009; 44(9): 571-577.
34. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-vina M, Filipovich A, Horowitz M et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood. 2004; 104(7): 1923-1930.
35. Sasazuki T, Juji T, Morishima Y, Kinukawa N, Kashiwabara H, Inoko H et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med. 1998; 339(17): 1177-1185.
36. Michallet M, Sobh M, Serrier C, Morisset S, Labussiere H, Ducastelle S et al. Allogeneic hematopoietic stem cell transplant for hematological malignancies from mismatched 9/10 human leukocyte antigen unrelated donors: comparison with transplants from 10/10 unrelated donors and human leukocyte antigen identical siblings. Leuk Lymphoma. 2015; 56(4): 999-1003.
37. Jorge AS, Lledó MS, Pereira A, et al. Single Antigen–Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors. Biol Blood Marrow Transplant. 2018;24(6):1196–1202.
38. Binkert L, Medinger M, Halter JP, Heim D, Gerull S, Holbro A et al. Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation. Bone Marrow Transplant. 2015; 50(10): 1331–1336.
39. Mielcarek M, Furlong T, O’Donnell PV, Storer BE, McCune JS, Storb R et al. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood. 2016; 127(11): 1502–1508.
40. Oran B, Manero GG, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO et al. Posttransplantation Cyclophosphamide Improves Transplantation Outcomes in Patients With AML/MDS Who Are Treated With Checkpoint Inhibitors. Cancer. 2020; 126(10): 2193-2205.
41. Schoch LK, Cooke KR, Wagner-Johnston ND, Gojo I, Swinnen LJ, Imus P et al. Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv. 2018; 2(17): 2226-2229.
42. Pasquini MC, Logan B, Jones RJ, Alousi AM, Appelbaum FR, Bolaños-Meade J et al. Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. Biol Blood Marrow Transplant. 2018; 24(6): 1274-1280.
43. Solomon SR, Sanacore M, Zhang X, Brown S, Holland K, Morris LE et al. Calcineurin inhibitor-free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2014; 20(11): 1828–1834.
44. Majzner RG, Mogri H, Varadhan R, Brown P, Cooke KR, Meade JB et al. Post-Transplant Cyclophosphamide after Bone Marrow Transplantation is not Associated with an Increased Risk of Donor Derived Malignancy. Biol Blood Marrow Transplant. 2017; 23(4): 612–617.
2. Bashey ZA, Zhang X, Brown S, Jackson K, Morris LE, Holland HK et al. Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older. Bone Marrow Transplant. 2018; 53(6): 756-763.
3. Barkhordar M, Kasaeian A, Tavakoli S, Vaezi M, Foumani HK, Bahri T et al. Selection of Suitable Alternative Donor in the Absence of Matched Sibling Donor: A Retrospective Single-Center Study to Compare between Haploidentical, 10/10 and 9/10 Unrelated Donor Transplantation. Int J Hematol Oncol Stem Cell Res. 2021; 15(1): 51-60.
4. Greco R, Lorentino F, Albanese S, Lupo Stanghellini MT, Giglio F, Piemontese S et al. Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. Transplant Cell Ther. 2021; 27(9): 776.e1-776.e13.
5. Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR et al. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biol Blood Marrow Transplant. 2019; 25(1): 73-85.
6. Aversa F, Pierini A, Ruggeri L, Martelli MF, Velardi A. The Evolution of T Cell Depleted Haploidentical Transplantation. Front Immunol. 2019; 10: 2769.
7. de Witte M, Daenen LGM, van der Wagen L, van Rhenen A, Raymakers R, Westinga K et al. Allogeneic Stem Cell Transplantation Platforms With Ex Vivo and In Vivo Immune Manipulations: Count and Adjust. Hemasphere. 2021; 5(6): e580. doi:10.1097/HS9.0000000000000580.
8. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008; 14(6): 641-650.
9. Kanakry CG, Ganguly S, Zahurak M, Bolaños-Meade J, Thoburn C, Perkins B et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013; 5(211): 211ra157.
10. Williams L, Cirrone F, Cole K, Abdul-Hay M, Luznik L, Al-Homsi AS. Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation. Front Immunol. 2020: 11: 636.
11. Ruggeri A, Labopin M, Bacigalupo A, Afanasyev B, Cornelissen JJ, Elmaagacli A et al. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. J Hematol Oncol. 2018; 11(1): 40.
12. Carnevale-Schianca F, Caravelli D, Gallo S, Becco P, Paruzzo L, Poletto S et al. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GvHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. J Clin Med. 2021; 10(6): 1173.
13. Bradstock KF, Bilmon I, Kwan J, Micklethwaite K, Blyth E, Deren S et al. Single-Agent High-Dose Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Human Leukocyte Antigen-Matched Reduced-Intensity Peripheral Blood Stem Cell Transplantation Results in an Unacceptably High Rate of Severe Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2015; 21(5): 941-944.
14. Moiseev IS, Pirogova OV, Alyanski AL, Babenko EV, Gindina TL, Darskaya EI et al. Risk-adapted GVHD prophylaxis with post-transplantation cyclophosphamide in adults after related, unrelated, and haploidentical transplantations. Eur J Haematol. 2018; 100(5): 395-402.
15. Moiseev IS, Pirogova OV, Alyanski AL, Babenko EV, Gindina TL, Darskaya EI et al. Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil. Biol Blood Marrow Transplant. 2016; 22(6): 1037-1042.
16. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015; 21(3): 389-401.
17. Lee SJ. Classification systems for chronic graft-versus-host disease. Blood. 2017; 129(1): 30-37.
18. Boyiadzis M, Arora M, Klein JP, Hassebroek A, Hemmer M, Urbano-Ispizua A et al. Impact of chronic graftversus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia. Clin Cancer Res. 2015; 21(9): 2020–2028.
19. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010; 363(22): 2091–2101.
20. Ostronoff F, Ostronoff M, Souto-Maior AP, Domingues M, Sucupira A, Manso DA et al. Prospective trial of mycophenolate mofetilcyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies. Clin Transplant. 2009; 23(1): 33–38.
21. Ruutu T, van Biezen A, Hertenstein B, Henseler A, Garderet L, Passweg J et al. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2012; 47(11): 1459–1464.
22. Luznik L, Bolanos-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010; 115(16): 3224–3230.
23. Kanakry CG, O'Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M et al. Multi-institutional study of posttransplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014; 32(31): 3497–3505.
24. Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C et al. Phase II trial of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide after reduced-intensity busulfan/fludarabine conditioning for hematological malignancies. Biol Blood Marrow Transplant. 2015; 21(5): 906–912.
25. McCurdy SR, Kasamon YL, Kanakry CG, Bolaños -Meade J, Tsai HL, Showel MM et al. Comparable composite endpoints after HLA -matched and HLA -haploidentical transplantation with post -transplantation cyclophosphamide. Haematologica. 2017; 102(2): 391-400.
26. Kanakry CG, Tsai HL, Bolaños-Meade J, Smith BD, Gojo I, Kanakry JA et al. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014; 124(25): 3817–3827.
27. Jacoby E, Chen A, Loeb DM, Gamper CJ, Zambidis E, Llosa NJ et al. Single-agent post-transplantation cyclophosphamide as graftversus-host disease prophylaxis after human leukocyte antigen-matched related bone marrow transplantation for pediatric and young adult patients with hematologic malignancies. Biol Blood Marrow Transplant. 2016; 22(1): 112–118.
28. Holtick U, Chemnitz JM, Shimabukuro-Vornhagen A, Theurich S, Chakupurakal G, Krause A et al. OCTET - CY: a phase II study to investigate the efficacy of post -transplant cyclophosphamide as sole graft -versus -host prophylaxis after allogeneic peripheral blood stem cell transplantation. Eur J Haematol. 2016; 96(1): 27-35.
29. Mehta RS, Saliba RM, Chen J, Rondon G, Hammerstrom AE, Alousi A et al. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol. 2016; 173(3): 444-455.
30. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007; 110(13): 4576-4583.
31. Petersdorf EW, Anasetti C, Martin PJ, Gooley T, Radich J, Malkki M et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood. 2004; 104(9): 2976-2980.
32. Woolfrey A, Klein JP, Haagenson M, Spellman S, Petersdorf E, Oudshoorn M et al. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2011; 17(6): 885-892.
33. Crocchiolo R, Ciceri F, Fleischhauer K, Oneto R, Bruno B, Pollichieni S et al. HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry. Bone Marrow Transplant. 2009; 44(9): 571-577.
34. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-vina M, Filipovich A, Horowitz M et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood. 2004; 104(7): 1923-1930.
35. Sasazuki T, Juji T, Morishima Y, Kinukawa N, Kashiwabara H, Inoko H et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med. 1998; 339(17): 1177-1185.
36. Michallet M, Sobh M, Serrier C, Morisset S, Labussiere H, Ducastelle S et al. Allogeneic hematopoietic stem cell transplant for hematological malignancies from mismatched 9/10 human leukocyte antigen unrelated donors: comparison with transplants from 10/10 unrelated donors and human leukocyte antigen identical siblings. Leuk Lymphoma. 2015; 56(4): 999-1003.
37. Jorge AS, Lledó MS, Pereira A, et al. Single Antigen–Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors. Biol Blood Marrow Transplant. 2018;24(6):1196–1202.
38. Binkert L, Medinger M, Halter JP, Heim D, Gerull S, Holbro A et al. Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation. Bone Marrow Transplant. 2015; 50(10): 1331–1336.
39. Mielcarek M, Furlong T, O’Donnell PV, Storer BE, McCune JS, Storb R et al. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood. 2016; 127(11): 1502–1508.
40. Oran B, Manero GG, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO et al. Posttransplantation Cyclophosphamide Improves Transplantation Outcomes in Patients With AML/MDS Who Are Treated With Checkpoint Inhibitors. Cancer. 2020; 126(10): 2193-2205.
41. Schoch LK, Cooke KR, Wagner-Johnston ND, Gojo I, Swinnen LJ, Imus P et al. Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv. 2018; 2(17): 2226-2229.
42. Pasquini MC, Logan B, Jones RJ, Alousi AM, Appelbaum FR, Bolaños-Meade J et al. Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. Biol Blood Marrow Transplant. 2018; 24(6): 1274-1280.
43. Solomon SR, Sanacore M, Zhang X, Brown S, Holland K, Morris LE et al. Calcineurin inhibitor-free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2014; 20(11): 1828–1834.
44. Majzner RG, Mogri H, Varadhan R, Brown P, Cooke KR, Meade JB et al. Post-Transplant Cyclophosphamide after Bone Marrow Transplantation is not Associated with an Increased Risk of Donor Derived Malignancy. Biol Blood Marrow Transplant. 2017; 23(4): 612–617.
| Files | ||
| Issue | Vol 18 No 3 (2024) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijhoscr.v18i3.16103 | |
| Keywords | ||
| Cyclophosmaide Graft-versus-host disease Post-transplant Prophylaxis Unrelated-donor | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Yıldırım M, Sayın S, Cömert M, Şafak, Yılmaz E, Avcu F, Ural A, Aylı M. Comparison of Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis after “Allogeneic Stem Cell Transplantation from 9/10 HLA Matched Unrelated Donor’’ with Standard Graft Versus Host Disease Prophylaxis after “10/10 HLA Matched Relative Donor’’ Tr. Int J Hematol Oncol Stem Cell Res. 2024;18(3):227-239.
